<DOC>
	<DOCNO>NCT00697931</DOCNO>
	<brief_summary>The purpose study compare immunogenicity reactogenicity adjuvanted recombinant hepatitis B vaccine Engerix™-B inject accord three dose schedule ( 0 , 1 , 6 month ) adult non-responder population</brief_summary>
	<brief_title>Immunogenicity Reactogenicity MPL Adjuvanted Recombinant Hepatitis B- Vaccine Engerix™-B Adult Non-Responders</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age : old 18 year age . Documented nonresponders 2 5 month receive 4 dos hepatitis B vaccine Good physical condition establish clinical examination history take time entry . Female participant risk become pregnant contraceptive programme necessary study period . Written inform consent obtain subject Positive screen antiHBV antibody Elevated serum liver enzyme . History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Any acute disease moment entry . Chronic alcohol consumption . Hepatomegaly , right upper quadrant abdominal pain tenderness . Any chronic drug treatment , include treatment immunosuppressive drug , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Simultaneous participation clinical trial . Previous vaccination MPL contain vaccine . Administration immunoglobulins 6 month whole study period Vaccination one month one month dose study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Engerix™-B</keyword>
	<keyword>Recombinant Hepatitis B vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>